3 results for Gluckman, Peter, Patent

  • Effects of Glycyl-2-methylprolylglutamate on Neurodegeneration

    Gluckman, Peter; Thomas, GB; Guan, J; Dragunow, M; Anand, Ashmit; Kerlero de Rosbo, N; Sieg, F; Brimble, Margaret (2007-12-27)

    Patent
    The University of Auckland Library

    This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.

    View record details
  • Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate

    Gluckman, Peter; Brimble, Margaret; Wilson, D; Tortella, FC; Williams, AJ; Xi-Chun, ML; Hartings, JA; Gryder, D (2010-05-11)

    Patent
    The University of Auckland Library

    Aspects of this invention include the use of G-2MePE to treat patients with brain injury characterized by non-convulsive seizures. G-2MePE is useful in treating brain injuries caused by traumatic brain injury, stroke, hypoxia/ischemia and toxic injury.

    View record details
  • Cognitive Enhancement and Cognitive Therapy Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid

    Gluckman, Peter; Guan, Jian; Woodworth, M; Brimble, Margaret

    Patent
    The University of Auckland Library

    This invention provides compounds, compositions and methods for treating loss of cognitive function in animals that results from aging. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic neurotransmitter, and can improve memory and cognitive function in animals who have experienced a loss of memory or cognitive function as a result of aging.

    View record details